Highest-materiality recent filing
Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; shares to be delisted
Total consideration ~USD$3.47M for 2,043,719 shares not already owned by Hanmi.
Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; deal closed
Aptose shareholders receive C$2.41 per share, a 28% premium over 30-day VWAP of C$1.88.
Aptose TUSCANY trial shows 86.2% CRc in newly diagnosed AML; all TP53-mut respond
Composite complete response (CRc) rate 86.2% in evaluable patients across all TUS+VEN+AZA dose groups.
Aptose delays Hanmi acquisition closing to June 2026 on pending Korean regulatory approvals
Closing of plan of arrangement with Hanmi delayed to June 2026 as Korean regulatory approvals remain in progress; parties expect closing to occur.
Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA
Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.
Aptose delays closing of Hanmi arrangement; targets May 2026 for completion
Closing delayed as Korean regulatory approvals remain in progress; parties do not anticipate prevention.
Aptose shareholders approve Hanmi go-private at C$2.41/share; FY net loss $25.5M
Shareholders approved acquisition by Hanmi at C$2.41/share (28% premium over 30-day VWAP of C$1.88).
Aptose shareholders approve continuance to Alberta and Hanmi acquisition arrangement
Continuance from CBCA to Alberta approved with 92.42% votes in favor.
Glass Lewis backs Aptose's plan for Hanmi acquisition; vote deadline March 27
Glass Lewis recommends shareholders vote FOR the arrangement with Hanmi and the continuance to ABCA.
ISS recommends Aptose shareholders vote FOR Hanmi arrangement at C$2.41/share
ISS recommends voting FOR the arrangement with Hanmi Pharmaceutical and the continuance to ABCA.
Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan
Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.
Aptose presents tuspetinib triplet therapy data at ASH: 100% CR/CRh at higher doses in AML
90% CR/CRh across all doses (40/80/120 mg TUS); 100% at 80 mg and 120 mg levels.
Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash
Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.
Aptose to be acquired by Hanmi Pharmaceutical at C$2.41/share, 28% premium to 30-day VWAP
Hanmi already owns 19.93% and provided >US$30M in debt facilities over 18 months.
Aptose reports Q3 net loss $5.1M, cash $1.6M, but TUS+VEN+AZA shows 100% CR/CRh at higher doses
Net loss $5.1M (-$2.01/share) for Q3 2025 vs $7.0M (-$11.33/share) in Q3 2024; nine-month net loss $17.7M.
Aptose tuspetinib combo achieves 100% CR/CRh at higher doses in newly diagnosed AML trial
TUS+VEN+AZA achieved 100% CR/CRh (6/6) at 80mg and 120mg doses, exceeding 66% expected from VEN+AZA alone.
Aptose secures $11.9M loan from Hanmi to fund tuspetinib AML study
Amended facility with Hanmi provides up to $11.9M in uncommitted advances through Dec 31, 2025; first advance expected soon.
Aptose reports tuspetinib triplet achieves 90% CR/CRh in newly diagnosed AML Phase 1/2 trial
100% CR/CRh at 80 mg and 120 mg TUS doses in combination with VEN+AZA (9/10 subjects).
Aptose Q2 net loss $7.0M; cash $1.3M; CSRC okays TUS dose escalation to 160 mg
Net loss $7.0M ($2.76 per share) for Q2 2025, vs. $7.3M in Q2 2024; loss per share improved on higher share count.
Aptose TUSCANY trial advances to 160 mg TUS dose; receives additional $1.1M loan from Hanmi
CSRC approved escalation to 160 mg TUS dose after no dose-limiting toxicities at 40, 80, and 120 mg cohorts.
Aptose receives $2M advance from Hanmi under $8.5M loan facility for tuspetinib AML trial
Second advance brings total drawn to $4.5M under the $8.5M loan agreement with Hanmi.
Aptose defers interest payment on Hanmi loan to December 31, 2025
Interest for Dec 21, 2024–Mar 31, 2025, originally due June 27, 2025, deferred to Dec 31, 2025.
Aptose enters $8.5M loan agreement with Hanmi for tuspetinib AML development
Loan agreement with Hanmi for up to US$8.5M uncommitted facility to fund continued clinical development of tuspetinib.
CEO William Rice provides non-interest bearing, unsecured short-term cash advance to support payroll and obligations.
All 7 director nominees re-elected with ≥97.69% votes for.
Aptose's TUS+VEN+AZA triplet data selected for oral presentation at EHA 2025 Congress
Data from TUSCANY Phase 1/2 trial of tuspetinib (TUS) + venetoclax + azacitidine in newly diagnosed AML accepted for oral presentation at EHA 2025 (June 12-15, Milan).
Aptose Q1 net loss $5.5M, cash only until end-May 2025; cites need for financing
Net loss of $5.5M for Q1 2025 vs. $9.6M a year ago; EPS loss $2.61.
Aptose TUSCANY trial: TUS+VEN+AZA triplet shows CRs, MRD negativity in high-risk AML
Four patients at 40 mg TUS+VEN+AZA: three achieved CR/CRi and MRD-negative, including a TP53-mutated/CK AML patient.
KPMG notifies Aptose it will not stand for re-appointment as auditor; material weakness disclosed
KPMG informed Aptose on Apr 15, 2025 it will not seek reappointment for the 2025 annual audit.
Aptose receives Nasdaq delisting notice for equity non-compliance; shares to be delisted Apr 2
Nasdaq determined to delist Aptose effective April 2, 2025 for failure to meet minimum stockholder equity requirement under Rule 5550(b)(1).
Aptose (APTO) to delist from Nasdaq April 2 for equity non-compliance
Nasdaq determined to delist Aptose common shares effective April 2, 2025 for failure to meet equity requirement (Listing Rule 5550(b)(1)).
Aptose reports FY 2024 net loss of $25.4M; cash runway to April 2025
Net loss $25.4M vs $51.2M in FY 2023; diluted EPS ($36.38) vs ($227.43).
Aptose converts $1.5M debt into 409,063 shares at $3.70; amends investor rights with Hanmi
Converted $1,513,533.10 of debt owed to Hanmi into 409,063 common shares at $3.70 per share.
Aptose gets CSRC approval to escalate TUS dose; CRs seen in difficult AML
CSRC unanimously approves dose escalation from 40 mg to 80 mg of tuspetinib in TUSCANY trial of TUS+VEN+AZA triplet.
On June 16, 2025, Carol Ashe notified the Board of Directors (the “Board”) of Aptose Biosciences Inc. (the “Company”) of her intention to resign from her role as a member of the Board effective immediately.
The amendment also added the title of Senior Vice President to Mr. Bejar’s position,
The amendment also added the titles of Chief Business Officer and Corporate Secretary to Mr. Payne’s position.
On September 13, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Dr. Bernd R. Seizinger, M.D., Ph.D. to its Board of Directors (the “Board”).
On June 27, 2022, Aptose Biosciences Inc. (“we” or the “Company”) appointed Mr. Fletcher Payne as its Senior Vice President and Chief Financial Officer.
On April 6, 2022, Aptose Biosciences Inc. appointed Mr. Philippe Ledru as its Chief Commercial Officer.
Aptose also announced on April 07, 2022 that Dr. Jotin Marango, Senior Vice President, Chief Financial Officer and Chief Business Officer, is resigning to pursue another opportunity.
Dr. Rice will serve as Chief Accounting Officer, and with Ms. Janet Clennett, Vice President of Finance, will assume financial responsibilities until a permanent CFO is announced.
Max materiality 1.00 · Median 0.65 · Most common event other_material